Calver J, Fabbri L, May J, Gisli Jenkins R
Clin Chest Med. 2023; 44(2):385-393.
PMID: 37085227
PMC: 9678841.
DOI: 10.1016/j.ccm.2022.11.013.
Humphrey T, Dosanjh D, Hiemstra T, Richter A, Chen-Xu M, Qian W
Trials. 2023; 24(1):185.
PMID: 36915199
PMC: 10009350.
DOI: 10.1186/s13063-023-07128-z.
Brodin D, Tornhammar P, Ueda P, Krifors A, Westerlund E, Athlin S
BMJ Open. 2023; 13(2):e064374.
PMID: 36813503
PMC: 9950582.
DOI: 10.1136/bmjopen-2022-064374.
Mortezaei Z, Mohammadian A, Tavallaei M
Heliyon. 2022; 8(7):e09910.
PMID: 35847618
PMC: 9271419.
DOI: 10.1016/j.heliyon.2022.e09910.
Tsuji G, Nakajima S, Watashi K, Torii S, Suzuki R, Fukuhara T
J Pharmacol Sci. 2022; 149(3):81-84.
PMID: 35641031
PMC: 9014634.
DOI: 10.1016/j.jphs.2022.04.001.
SARS-CoV-2 Infection and Lung Regeneration.
Zhao F, Ma Q, Yue Q, Chen H
Clin Microbiol Rev. 2022; 35(2):e0018821.
PMID: 35107300
PMC: 8809385.
DOI: 10.1128/cmr.00188-21.
Understanding COVID-19 Pathogenesis: A Drug-Repurposing Effort to Disrupt Nsp-1 Binding to Export Machinery Receptor Complex.
Vasudevan S, Baraniuk J
Pathogens. 2021; 10(12).
PMID: 34959589
PMC: 8709492.
DOI: 10.3390/pathogens10121634.
Efficacy of Inhaled Ciclesonide for Outpatient Treatment of Adolescents and Adults With Symptomatic COVID-19: A Randomized Clinical Trial.
Clemency B, Varughese R, Gonzalez-Rojas Y, Morse C, Phipatanakul W, Koster D
JAMA Intern Med. 2021; 182(1):42-49.
PMID: 34807241
PMC: 8609464.
DOI: 10.1001/jamainternmed.2021.6759.
Races of small molecule clinical trials for the treatment of COVID-19: An up-to-date comprehensive review.
Hu S, Jiang S, Qi X, Bai R, Ye X, Xie T
Drug Dev Res. 2021; 83(1):16-54.
PMID: 34762760
PMC: 8653368.
DOI: 10.1002/ddr.21895.
Ciclesonide Inhaler Treatment for Mild-to-Moderate COVID-19: A Randomized, Open-Label, Phase 2 Trial.
Song J, Yoon J, Seo Y, Lee J, Eom J, Lee J
J Clin Med. 2021; 10(16).
PMID: 34441840
PMC: 8396813.
DOI: 10.3390/jcm10163545.
Association of asthma comorbidity with poor prognosis of coronavirus disease 2019.
Kim S, Ji E, Won S, Cho J, Kim Y, Ahn S
World Allergy Organ J. 2021; 14(8):100576.
PMID: 34422204
PMC: 8364802.
DOI: 10.1016/j.waojou.2021.100576.
High Levels of the Cleaved Form of Galectin-9 and Osteopontin in the Plasma Are Associated with Inflammatory Markers That Reflect the Severity of COVID-19 Pneumonia.
Bai G, Furushima D, Niki T, Matsuba T, Maeda Y, Takahashi A
Int J Mol Sci. 2021; 22(9).
PMID: 34067072
PMC: 8125627.
DOI: 10.3390/ijms22094978.
Management of chronic pulmonary disease in the time of coronavirus disease 2019.
Palla J, Laguna T
Curr Opin Pediatr. 2021; 33(3):294-301.
PMID: 33938475
PMC: 8097727.
DOI: 10.1097/MOP.0000000000001017.
Tocilizumab and PMX-DHP have efficacy for severe COVID-19 pneumonia.
Shinomiya S, Nakase K, Fujii A, Takahara Y, Adachi H, Okuro M
SAGE Open Med Case Rep. 2021; 9:2050313X21991063.
PMID: 33796310
PMC: 7970680.
DOI: 10.1177/2050313X21991063.
A review on function and side effects of systemic corticosteroids used in high-grade COVID-19 to prevent cytokine storms.
Langarizadeh M, Tavakoli M, Abiri A, Ghasempour A, Rezaei M, Ameri A
EXCLI J. 2021; 20:339-365.
PMID: 33746666
PMC: 7975631.
DOI: 10.17179/excli2020-3196.
COVID-19 severity in asthma patients: a multi-center matched cohort study.
Robinson L, Wang L, Fu X, Wallace Z, Long A, Zhang Y
J Asthma. 2021; 59(3):442-450.
PMID: 33650461
PMC: 7938653.
DOI: 10.1080/02770903.2020.1857396.
Asthma in Adult Patients with COVID-19. Prevalence and Risk of Severe Disease.
Terry P, Heidel R, Dhand R
Am J Respir Crit Care Med. 2021; 203(7):893-905.
PMID: 33493416
PMC: 8017581.
DOI: 10.1164/rccm.202008-3266OC.
Detailed Molecular Interactions of Favipiravir with SARS-CoV-2, SARS-CoV, MERS-CoV, and Influenza Virus Polymerases In Silico.
Sada M, Saraya T, Ishii H, Okayama K, Hayashi Y, Tsugawa T
Microorganisms. 2020; 8(10).
PMID: 33092045
PMC: 7589801.
DOI: 10.3390/microorganisms8101610.
The Inhaled Steroid Ciclesonide Blocks SARS-CoV-2 RNA Replication by Targeting the Viral Replication-Transcription Complex in Cultured Cells.
Matsuyama S, Kawase M, Nao N, Shirato K, Ujike M, Kamitani W
J Virol. 2020; 95(1).
PMID: 33055254
PMC: 7737752.
DOI: 10.1128/JVI.01648-20.
Antiviral Potential of Nanoparticles-Can Nanoparticles Fight Against Coronaviruses?.
Gurunathan S, Qasim M, Choi Y, Do J, Park C, Hong K
Nanomaterials (Basel). 2020; 10(9).
PMID: 32825737
PMC: 7557932.
DOI: 10.3390/nano10091645.
